Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation.

abstract：:Emerging evidence has shown that microRNAs (miRNAs) can act as oncogenes in the initiation and progression of leukemia and lymphoma. Aberrant expression of oncogenic miRNAs, including miR-155, miR-17-92, miR-21, miR-125b, miR-93, miR-143-p3, miR-196b, and miR-223 promotes leukemogenesis through increasing the leukemic...

journal_title：Current pharmaceutical design

authors： Pan Y,Meng M,Zhang G,Han H,Zhou Q

更新日期：2014-01-01 00:00:00

abstract：:Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) isoforms present in the eyes (CA I, II, IV and XII), with sulfonamides such as acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide, is still widely used for the systemic treatment of glaucoma. The mechanism of action of these drugs consists in inhibition ...

journal_title：Current pharmaceutical design

authors： Mincione F,Scozzafava A,Supuran CT

更新日期：2008-01-01 00:00:00

abstract：:Effective blood pressure control with a large arsenal of conventional antihypertensive drugs, such as diuretics, beta-adrenergic blockers, and calcium channel blockers, significantly reduce the morbidity and mortality associated with cardiovascular disease. However, blood pressure control with these drugs does not red...

journal_title：Current pharmaceutical design

authors： Igic R,Behnia R

更新日期：2007-01-01 00:00:00

abstract：:Many, if not all, chronic medical, neurodegenerative and neuroprogressive illnesses are characterised by chronic immune activation, oxidative and nitrosative stress (O&NS) and systemic inflammation. These factors, notably elevated pro-inflammatory cytokines, activate indoleamine 2,3-dioxygenase (IDO) leading to an upr...

journal_title：Current pharmaceutical design

authors： Morris G,Carvalho AF,Anderson G,Galecki P,Maes M

更新日期：2016-01-01 00:00:00

abstract：:Tumor metastasis is an important prognostic factor regarding long-term survival rate of cancer patients. At present, no imaging modality or technique is ideal for diagnosis of metastases. Molecular imaging has provided a fantastic tool for tumor metastases imaging. Based on the current medical imaging tools such as ma...

journal_title：Current pharmaceutical design

authors： Qiao R,Zhu R,Gao M

更新日期：2015-01-01 00:00:00

abstract：:The nanodelivery of therapeutics into the brain will require a step-change in thinking; overcoming the blood brain barrier is one of the major challenges to any neural therapy. The promise of nanotechnology is that the selective delivery of therapeutics can be delivered through to the brain without causing secondary d...

journal_title：Current pharmaceutical design

authors： Ellis-Behnke RG,Teather LA,Schneider GE,So KF

更新日期：2007-01-01 00:00:00

abstract：:Sulphur mustard (SM; (2, 2'-dichloroethylsulfide)) was used for the first time in 1917, during the World War I. SM mainly induces DNA damage, oxidative stress, and inflammation. This compound injures the respiratory system, eyes, skin and the endocrine, gastrointestinal, and hematopoietic systems. However, due to the ...

journal_title：Current pharmaceutical design

authors： Panahi Y,Shahbazi A,Naderi M,Jadidi K,Sahebkar A

更新日期：2018-01-01 00:00:00

abstract：:Gene therapy, currently, represents one of the new therapies that have emerged for the treatment of different diseases. Between the different approaches that can be chosen concerning this therapy, gene delivery with non-viral systems has focused the attention during the past decades, because of the reduced toxicity co...

journal_title：Current pharmaceutical design

authors： Urbiola K,Blanco-Fernandez L,de Ilarduya CT

更新日期：2015-01-01 00:00:00

abstract：:A better knowledge of the mechanisms underlying hepatocellular carcinoma (HCC) growth and spread is essential to improve the available treatment options. So far, the only therapies available for HCC are mainly based on tumor-destructive approaches, whereas no therapies are available to consolidate these invasive thera...

journal_title：Current pharmaceutical design

authors： Antonaci S,Giannelli G

更新日期：2007-01-01 00:00:00

abstract：:Population studies have identified diabetes mellitus as a risk factor for cardiac and vascular events, with a common association with hypertension. Observational studies have consistently demonstrated blood glucose as a continuous cardiovascular risk factor. Experimental studies suggest that elevated blood glucose, th...

journal_title：Current pharmaceutical design

authors： Lim HS,MacFadyen RJ,Bakris G,Lip GY

更新日期：2006-01-01 00:00:00

abstract：:Although the cause of Crohn's disease remains unknown considerable progress has been made in recent years to unravel the pathogenesis of the inflammatory processes seen in chronic idiopathic inflammatory bowel diseases (IBD). Th-1 lymphocytes seem to orchestrate the inflammation through the production of pro-inflammat...

journal_title：Current pharmaceutical design

authors： D'Haens G

更新日期：2003-01-01 00:00:00

abstract：:Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially co...

journal_title：Current pharmaceutical design

authors： Florentin M,Elisaf MS,Mikhailidis DP,Liberopoulos EN

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Erectile dysfunction (ED) is an evolving health problem in the aging male population. Chronic low-grade inflammation is a critical component of ED pathogenesis and a probable intermediate stage of endothelial dysfunction, especially in metabolic diseases, with the inclusion of obesity, metabolic syndrome, an...

journal_title：Current pharmaceutical design

authors： Kaya-Sezginer E,Gur S

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:The use of essential oils is receiving increasing attention worldwide, as these oils are good sources of several bioactive compounds. Nowadays essential oils are preferred over synthetic preservatives thanks to their antioxidant and antimicrobial properties. Several studies highlight the beneficial effect of...

journal_title：Current pharmaceutical design

authors： Ferrentino G,Morozova K,Horn C,Scampicchio M

更新日期：2020-01-01 00:00:00

abstract：:Ras is a 21 kDa membrane-localized G protein that is coupled to receptor and non-receptor tyrosine kinase activation of downstream cytoplasmic and nuclear events. Mutated ras genes are common, and occur in a wide variety of human malignancies. These activating mutations result in constitutive signaling, thereby stimul...

journal_title：Current pharmaceutical design

authors： Adjei AA

更新日期：2001-11-01 00:00:00

abstract：:Increased plasma levels of both leptin and C reactive protein (CRP) have been reported in a number of conditions, including obesity, and have been linked to cardiovascular pathophysiological processes and increased cardiovascular risk; interestingly these two biomarkers appear to be able to reciprocally regulate their...

journal_title：Current pharmaceutical design

authors： Hribal ML,Fiorentino TV,Sesti G

更新日期：2014-01-01 00:00:00

abstract：:Understanding of the roles of RNAs within the cell has changed and expanded dramatically during the past few years. Based on fundamentally new insights it is now increasingly possible to employ RNAs as highly valuable tools in molecular biology and medicine. At present, the most important therapeutic strategies are ba...

journal_title：Current pharmaceutical design

authors： Poller W,Fechner H

更新日期：2010-01-01 00:00:00

abstract：:The epidermal growth factor receptor (EGFR) has been widely used as a target for novel anticancer agents, such as blocking antibodies and small molecular weight tyrosine kinase compounds. In spite of recent advances in cancer cell biology, leading to the introduction of clinically active new drugs, such as cetuximab, ...

journal_title：Current pharmaceutical design

authors： Bianco R,Damiano V,Gelardi T,Daniele G,Ciardiello F,Tortora G

更新日期：2007-01-01 00:00:00

abstract：:We have synthesized a novel series of N-substituted sarcosines, analogues of NFPS (N-[3-(biphenyl-4- yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine), as type-1 glycine transporter (GlyT-1) inhibitors. Several compounds incorporated a diazine ring inhibited recombinant hGlyT-1b expressed permanently in CHO cells and ...

journal_title：Current pharmaceutical design

authors： Harsing LG Jr,Timar J,Szabo G,Udvari S,Nagy KM,Marko B,Zsilla G,Czompa A,Tapolcsanyi P,Kocsis A,Matyus P

更新日期：2015-01-01 00:00:00

abstract：:The metabolic syndrome (MetS) represents a cluster of medical disorders, such as hyperglycemia, dyslipidemia, hypertension, and abdominal obesity that, when occurring together, increase the risk of developing cardiovascular disease. The role of food and nutrients in the aetiology of chronic diseases has become clearer...

journal_title：Current pharmaceutical design

authors： Grosso G,Mistretta A,Marventano S,Purrello A,Vitaglione P,Calabrese G,Drago F,Galvano F

更新日期：2014-01-01 00:00:00

abstract：:The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 inte...

journal_title：Current pharmaceutical design

authors： Blasi F

更新日期：2011-01-01 00:00:00

abstract：:The so-called demographic transition has changed the age structure of the population worldwide, with profound effects on societal organization. The growing number and percentage of old and very old people has compelled the scientific community to focus on age related diseases and peculiar consequences of aging itself ...

journal_title：Current pharmaceutical design

authors： Paganelli R,Di Iorio A,Cherubini A,Lauretani F,Mussi C,Volpato S,Abate M,Abate G,Ferrucci L

更新日期：2006-01-01 00:00:00

abstract：:Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid i...

journal_title：Current pharmaceutical design

authors： Zuardi AW,Crippa JA,Hallak JE,Bhattacharyya S,Atakan Z,Martin-Santos R,McGuire PK,Guimarães FS

更新日期：2012-01-01 00:00:00

abstract：:Lysine acetylation plays an essential role in metabolism. Five individual studies have identified that a large number of cellular proteins are potentially acetylated. Notably, almost every enzyme involved in central metabolic pathways such as glycolysis, the TCA cycle, fat acid metabolism, urea cycle and glycogen meta...

journal_title：Current pharmaceutical design

authors： Lin R,Zhou X,Huang W,Zhao D,Lv L,Xiong Y,Guan KL,Lei QY

更新日期：2014-01-01 00:00:00

abstract：AIM:The effect of endovascular aneurysm repair in patients treated for abdominal aortic aneurysm has not been clearly defined. The objective of the present article was to provide a contemporary literature review and perform an analysis to determine the effect of EVAR on renal function in the early post-operative period...

journal_title：Current pharmaceutical design

authors： Nana P,Kouvelos G,Brotis A,Spanos K,Giannoukas A,Matsagkas M

更新日期：2019-01-01 00:00:00

abstract：:The cytokine tumor necrosis factor(alpha) (TNF(alpha)) is associated with a constellation of physiological and behavioral characteristics that follow in response to infection such as fever, fatigue, listlessness, loss of appetite, malaise, and tactile hypersensitivity. These responses are examples of central nervous s...

journal_title：Current pharmaceutical design

authors： Hermann GE,Holmes GM,Rogers RC

更新日期：2005-01-01 00:00:00

abstract：:Post-traumatic stress disorder (PTSD) is an anxiety disorder that develops after experiencing trauma. Actual therapies do not help majority of patients with PTSD. Moreover, extinguished fear memories usually reappear in the individuals when exposed to trauma cues. New drugs to reduce the impact of conditioned cues in ...

journal_title：Current pharmaceutical design

authors： Barreto GE,Yarkov A,Avila-Rodriguez M,Aliev G,Echeverria V

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Reversible cholinesterase inhibitors, when given prophylactically before exposure to organophosphates, are able to decrease organophosphate-induced mortality. However, the efficacy of pyridostigmine, the only pre-treatment substance approved by the US Federal Drug Administration, is unsatisfactory. METHODS:...

journal_title：Current pharmaceutical design

authors： Lorke DE,Nurulain SM,Hasan MY,Kuca K,Petroianu GA

更新日期：2017-01-01 00:00:00

abstract：:Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural protein...

journal_title：Current pharmaceutical design

authors： Meeprasert A,Rungrotmongkol T,Li MS,Hannongbua S

更新日期：2014-01-01 00:00:00

abstract：:Drug hypersensitivity reactions (DHRs) represent a major burden on the healthcare system since their diagnostic and management are complex. As they can be influenced by individual genetic background, it is conceivable that the identification of variants in genes potentially involved could be used in genetic testing fo...

journal_title：Current pharmaceutical design

authors： Mayorga C,Montañez MI,Jurado-Escobar R,Gil-Ocaña V,Cornejo-García JA

更新日期：2019-01-01 00:00:00